Center for Breakthrough Medicines

King of Prussia, PA
AAV Lentiviral Plasmid
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
59.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (2)

Quick Facts: Center for Breakthrough Medicines

Signal Score
59.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
King of Prussia, PA
Modalities
AAV, Lentiviral, Plasmid
Active CGT Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Plasmid
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 CGT manufacturing site: King of Prussia, PA
Modalities: AAV, Lentiviral, Plasmid
Capacity assessment: 58.0/100
Sites: King of Prussia, PA
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
StatusExpanding
1 CGT manufacturing site: King of Prussia, PA
Modalities: AAV, Lentiviral, Plasmid
Capacity assessment: 58.0/100
Sites: King of Prussia, PA
Recent Press2 articles
1 CGT manufacturing site: King of Prussia, PA
Modalities: AAV, Lentiviral, Plasmid
Capacity assessment: 58.0/100

Recent News 2 articles

general 2026-03-16
ARPA-H Grants BioCurie Funds to Build Scalable Gene Therapy Manufacturing Platform - GEN - Genetic Engineering and Biotechnology News
ARPA-H Grants BioCurie Funds to Build Scalable Gene Therapy Manufacturing Platform  Genetic Engineering and Biotechnology News
Source →
general 2026-03-12
BioCurie Lands $9.3M ARPA-H Award to Build AI-Powered Gene Therapy Manufacturing Platform - BioBuzz
BioCurie Lands $9.3M ARPA-H Award to Build AI-Powered Gene Therapy Manufacturing Platform  BioBuzz
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs → Plasmid CDMOs →